A Boston federal judge criticized the pleadings in two unusual purported class actions against Genzyme Corp. over its rationing of the drug Fabrazyme, complaining that just one of more than 70 plaintiffs appears to have a valid claim.
The drug treats Fabry Disease, a potentially life-threatening inherited disorder stemming from the buildup of a particular type of fat in the body’s cells.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
